Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of HIV-specific CD8+ T cells in pediatric HIV cure strategies after widespread early viral escape.
Leitman EM, Thobakgale CF, Adland E, Ansari MA, Raghwani J, Prendergast AJ, Tudor-Williams G, Kiepiela P, Hemelaar J, Brener J, Tsai MH, Mori M, Riddell L, Luzzi G, Jooste P, Ndung'u T, Walker BD, Pybus OG, Kellam P, Naranbhai V, Matthews PC, Gall A, Goulder PJR. Leitman EM, et al. Among authors: naranbhai v. J Exp Med. 2017 Nov 6;214(11):3239-3261. doi: 10.1084/jem.20162123. Epub 2017 Oct 5. J Exp Med. 2017. PMID: 28983013 Free PMC article.
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
Mureithi MW, Poole D, Naranbhai V, Reddy S, Mkhwanazi NP, Sibeko S, Werner L, Abdool Karim Q, Abdool Karim S, Ndung'u T, Altfeld M; CAPRISA004 Trial Group. Mureithi MW, et al. Among authors: naranbhai v. J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):124-7. doi: 10.1097/QAI.0b013e31824f53a9. J Acquir Immune Defic Syndr. 2012. PMID: 22362152 Free PMC article.
Neither microbial translocation nor TLR responsiveness are likely explanations for preexisting immune activation in women who subsequently acquired HIV in CAPRISA 004.
Naranbhai V, Samsunder N, Sandler NG, Roque A, Abdool Karim Q, Ndungʼu T, Carr WH, Altfeld M, Douek DC, Abdool Karim SS; CAPRISA 004 Trial Team. Naranbhai V, et al. J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):294-8. doi: 10.1097/QAI.0b013e31828e604b. J Acquir Immune Defic Syndr. 2013. PMID: 23481666 Free PMC article. Clinical Trial.
No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.
Chopera DR, Mann JK, Mwimanzi P, Omarjee S, Kuang XT, Ndabambi N, Goodier S, Martin E, Naranbhai V, Karim SA, Karim QA, Brumme ZL, Ndung'u T, Williamson C, Brockman MA; CAPRISA 004 TRAPS Team. Chopera DR, et al. Among authors: naranbhai v. PLoS One. 2013 Aug 28;8(8):e71758. doi: 10.1371/journal.pone.0071758. eCollection 2013. PLoS One. 2013. PMID: 24015191 Free PMC article.
109 results